Respiratory Distress Syndrome is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Respiratory Distress Syndrome have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Respiratory Distress Syndrome compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Respiratory Distress Syndrome overview

Respiratory distress syndrome (RDS) occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have RDS and need extra oxygen and help breathing. It primarily affects premature infants due to insufficient surfactant, a lung-stabilizing substance. Without surfactant, the lungs collapse, causing breathing difficulties. Common in preterm births, symptoms include rapid breathing, grunting, nostril flaring, and cyanosis. Prompt diagnosis and treatment, often involving mechanical ventilation and surfactant replacement, are vital. While RDS is more prevalent in premature babies, it can also affect full-term infants with specific risk factors. Proactive neonatal care and surfactant therapy enhance lung function, significantly improving the prognosis for infants with RDS. Early detection and intervention are critical for optimal outcomes in managing respiratory distress in newborns.

For a complete picture of PTSR and LoA scores for drugs in Respiratory Distress Syndrome, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.